In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.   

The Chan Zuckerberg Biohub New York (CZ Biohub NY) today announced nine new investigators to its growing roster of talented researchers. Joining from Columbia University, The Rockefeller University, and Yale University, the eight projects will focus on the Biohub’s mission to harness and bioengineer immune cells for the early detection, prevention, and treatment of a broad spectrum of age-related diseases, including neurodegenerative disorders and aggressive cancers. The funded projects support a variety of innovative strategies, including leveraging synthetic biology to address the limitations of current immune cell therapies and using models to enable insights into cellular networks and tissue adaptations in health and disease.

Professors Zhaoyang Zeng and Can Guo from the Xiangya School of Basic Medical Sciences, Central South University, in collaboration with Researcher Wenjia Guo from Xinjiang Medical University, have discovered a novel circular RNA, circTP63-N, encoded by the TP63 gene, which suppresses the malignant progression of nasopharyngeal carcinoma. This significant finding has been recently published in Science China Life Sciences.